Abstract
External counterpulsation (ECP) is an established therapy for symptomatic coronary heart disease, and is an emerging therapy for systolic heart failure. Here we report our experience with the impact of ECP on the heart failure status of 53 adult (age, mean +/− SEM, 71 +/− 1 years) patients (75% male) with ischemic cardiomyopathy and systolic dysfunction. NYHA Class, health satisfaction score utilizing visual analog scale (HSS), 6 minute walk distance in feet (6MW), LVEF, and B natriuretic peptide (BNP) were prospectively measured before and after a course of 34.6 + /- 0.5 hours of ECP therapy: We conclude that in our single center experience, ECP has a significant beneficial impact on the functional status of patients with ischemic cardiomyopathy and LV systolic dysfunction.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
